These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 23972517)
1. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition. Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517 [TBL] [Abstract][Full Text] [Related]
2. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition. Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089 [TBL] [Abstract][Full Text] [Related]
3. Unravelling survival pathways: the road to next-generation chronic myeloid leukaemia drugs? Deeren D Leuk Res; 2013 Nov; 37(11):1438-9. PubMed ID: 24075533 [No Abstract] [Full Text] [Related]
4. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1. Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787 [TBL] [Abstract][Full Text] [Related]
5. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway. Wei YL; Liang Y; Xu L; Zhao XY Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306 [TBL] [Abstract][Full Text] [Related]
6. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995 [TBL] [Abstract][Full Text] [Related]
7. Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance. Chakraborty JB; Mahato SK; Joshi K; Shinde V; Rakshit S; Biswas N; Choudhury Mukherjee I; Mandal L; Ganguly D; Chowdhury AA; Chaudhuri J; Paul K; Pal BC; Vinayagam J; Pal C; Manna A; Jaisankar P; Chaudhuri U; Konar A; Roy S; Bandyopadhyay S Cancer Sci; 2012 Jan; 103(1):88-99. PubMed ID: 21943109 [TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Holtz MS; Slovak ML; Zhang F; Sawyers CL; Forman SJ; Bhatia R Blood; 2002 May; 99(10):3792-800. PubMed ID: 11986238 [TBL] [Abstract][Full Text] [Related]
10. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
11. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells. Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793 [TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor. Nagao R; Ashihara E; Kimura S; Strovel JW; Yao H; Takeuchi M; Tanaka R; Hayashi Y; Hirai H; Padia J; Strand K; Maekawa T Cancer Lett; 2011 Dec; 312(1):91-100. PubMed ID: 21906872 [TBL] [Abstract][Full Text] [Related]
13. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment. Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838 [TBL] [Abstract][Full Text] [Related]
15. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib. Dong Y; Xiong M; Duan L; Liu Z; Niu T; Luo Y; Wu X; Xu C; Lu C Apoptosis; 2014 Aug; 19(8):1281-92. PubMed ID: 24830786 [TBL] [Abstract][Full Text] [Related]
16. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. Marley SB; Lewis JL; Schneider H; Rudd CE; Gordon MY Br J Haematol; 2004 May; 125(4):500-11. PubMed ID: 15142121 [TBL] [Abstract][Full Text] [Related]
17. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456 [TBL] [Abstract][Full Text] [Related]
18. Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells. Yang H; Hui H; Wang Q; Li H; Zhao K; Zhou Y; Zhu Y; Wang X; You Q; Guo Q; Lu N Oncotarget; 2014 Sep; 5(18):8188-201. PubMed ID: 25149543 [TBL] [Abstract][Full Text] [Related]